SFAM
JANX icon

Springhill Fund Asset Management’s Janux Therapeutics JANX Stock Holding History

Springhill Fund Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-78,500
Closed -$2.12M – 7
2025
Q1 		$2.12M Buy
78,500
+48,900
+165% +$1.84M 10.16% 3
2024
Q4 		$1.58M Buy
+29,600
New +$1.57M 2.57% 15

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Springhill Fund Asset Management's JANX Position: Q2 2025 in Review

Springhill Fund Asset Management sold out of Janux Therapeutics (JANX) in Q2 2025, closing a stake of 78,500 shares — an estimated $2.12M sold.

Springhill Fund Asset Management first reported a position in JANX in Q4 2024 and held it in 2 quarters. The position peaked at $2.12M in Q1 2025. 174 funds tracked by Wall St. Rank hold JANX as of Q2 2025.

  • Springhill Fund Asset Management reported no remaining Janux Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Springhill Fund Asset Management sold 78,500 Janux Therapeutics shares in Q2 2025, an estimated $2.12M.
  • Springhill Fund Asset Management first reported a position in Janux Therapeutics in Q4 2024 and held it in 2 quarters.
  • Springhill Fund Asset Management's Janux Therapeutics position peaked at $2.12M in Q1 2025.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2025.

Based on Springhill Fund Asset Management's 13F filing for Q2 2025.